계명대학교 의학도서관 Repository

Impact of adjuvant treatments on survival in Korean patients with WHO grade II gliomas: KNOG 15-02 and KROG 16-04 intergroup study

Metadata Downloads
Author(s)
Taeryool KooDo Hoon LimHo Jun SeolYun‑Sik DhoIl Han KimJong Hee ChangJeongshim LeeTae‑Young JungHo‑Shin GwakKwan Ho ChoChang‑Ki HongIk Jae LeeEl KimJin Hee KimYong‑Kil HongHong Seok JangChae‑Yong KimIn Ah KimSung Hwan KimYoung Il KimEun‑Young KimWoo Chul KimSemie Hong
Keimyung Author(s)
Kim, ElKim, Jin Hee
Department
Dept. of Neurosurgery (신경외과학)
Dept. of Radiation Oncology (방사선종양학)
Journal Title
Journal of Neuro-Oncology
Issued Date
2018
Volume
140
Issue
2
Keyword
Low-grade gliomaSurvivalAdjuvant treatmentRadiotherapyChemotherapy
Abstract
Introduction
Optimal treatment strategies for low-grade glioma (LGG) remain controversial. We analyzed treatment outcomes and evaluated prognostic factors of adult LGG patients in Korea.

Methods
We reviewed the medical records of 555 patients diagnosed with WHO grade II LGG (astrocytoma 37.8%, oligoastrocytoma 15.3%, and oligodendroglioma 46.8%) at 14 institutions between 2000 and 2010. Primary and secondary endpoints were progression-free survival (PFS) and overall survival (OS). Propensity-score matching (PSM) analyses were performed to correct imbalances in patient/tumor characteristics among adjuvant treatment groups.

Results
The median follow-up time was 83.4 months, and the 5-year PFS and OS rates were 52.2% and 83.0%, respectively. Male, older age, poorer performance status, multiple lobe involvement, and astrocytoma histology were associated with poorer survival. Among the treatment factors, gross total resection (GTR) was associated with better PFS and OS, and adjuvant chemotherapy with improved PFS. Interestingly, adjuvant radiotherapy (RT) did not improve PFS; rather, it was related with poorer OS. Regarding patient/tumor characteristics, the RT group had poorer characteristics than the non-RT group. After PSM, we detected a tendency for improved PFS in the matched RT group, and no significant difference in OS compared with the matched non-RT group.

Conclusions
The achievement of GTR is important to improve survival in LGG patients. Adjuvant chemotherapy may enhance PFS, but adjuvant RT did not improve survival outcomes. After PSM, we observed potential impacts of adjuvant RT on PFS. Our results may reflect real-world practice and consequently may help to optimize treatment strategies for LGG
Keimyung Author(s)(Kor)
김 엘
김진희
Publisher
School of Medicine (의과대학)
Citation
Taeryool Koo et al. (2018). Impact of adjuvant treatments on survival in Korean patients with WHO grade II gliomas: KNOG 15-02 and KROG 16-04 intergroup study. Journal of Neuro-Oncology, 140(2), 445–455. doi: 10.1007/s11060-018-2972-8
Type
Article
ISSN
1573-7373
Source
https://link.springer.com/article/10.1007%2Fs11060-018-2972-8
DOI
10.1007/s11060-018-2972-8
URI
https://kumel.medlib.dsmc.or.kr/handle/2015.oak/41757
Appears in Collections:
1. School of Medicine (의과대학) > Dept. of Neurosurgery (신경외과학)
1. School of Medicine (의과대학) > Dept. of Radiation Oncology (방사선종양학)
공개 및 라이선스
  • 공개 구분공개
  • 엠바고Forever
파일 목록

Items in Repository are protected by copyright, with all rights reserved, unless otherwise indicated.